Clinical Trial Update: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

This entry reports an ongoing Phase 1/2 clinical trial evaluating the combination of avelumab and pepinemab as second-line therapy for metastatic pancreatic ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Avelumab (avelumab)
• Pepinemab (pepinemab)

Snippet

Sponsor: Vaccinex Inc. | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING